Media Coverage

Minuum to end battle between mobile screen space and virtual keyboards

Start-up launches Indiegogo campaign to change future of mobile typing

Minuum keyboard on an Android phone — The Minuum keyboard: “the little keyboard for big fingers.” Designed by Whirlscape Inc., this one-dimensional, tiny keyboard frees up mobile screen space while allowing fast, accurate typing.

TORONTO, March 18, 2013 — Whirlscape Inc., a Canadian tech start-up, has developed Minuum, “the little keyboard for big fingers.”

Updated: The company has now cleared its $60,000 stretch goal to build a wearable development kit. Read the Mobile Syrup follow-up story.

Minuum’s crowdfunding campaign was covered by the Financial Post, CBC News, CTV News, the Toronto Star and Metro Morning (radio interview). They also did a second spot on CTV News‘s Tech Tuesday report and were featured on Global TV’s The Morning Show.

The story was also picked up by Fast Company, Mashable, CNET, TechCrunch, TechCrunch Japan, TechVibes, Huffington Post, Toronto Standard, BlogTO and Mobile Syrup.

Minuum is a tiny, one-dimensional keyboard that frees up mobile screen space while allowing fast, accurate typing. Its specialized, patent-protected auto-correction algorithm corrects highly imprecise typing.

This algorithm, based on the touchscreen and wearable device research of company founders, Will Walmsley (researcher) and Khai Truong (associate professor) at the University of Toronto, configures the difference between what you type and what you mean, in real time, getting it right even if you miss every single letter.

Crowdmark’s grading software featured in EdSurge

March 18, 2013
Susanne Staer
Crowdmark

Exam pain is not limited to students, notes Tony Wan of EdSurge in his profile of UTEST start-up company, Crowdmark.

The article, “Crowdmark Lends a Helping Hand with Handwritten Assessments: How one savvy professor is scaling human grading capabilities for handwritten responses” appeared Mar. 17, 2013.

Here’s an excerpt:

Dr. James Colliander, co-founder and CEO of Crowdmark. Photo courtesy of Denise Grant. Used with permission.

James Colliander, a Professor Mathematics at the University of Toronto, knew this pain all too well. As a grader for the 2011 Canadian Open Mathematics Challenge, he and a team of volunteers had to deal with 70,000 pages of hand-written responses, a “tremendously inefficient, logistical nightmare” that involved paper shuffling and moving boxes of exams.

That’s when he started working on a way to scale human assessment capabilities. In April 2011, Colliander joined UTEST (University of Toronto Early Stage Technology), an incubator launched by the University of Toronto and MaRS Innovation, to work on his solution, Crowdmark.

ScarX Therapeutics featured on cover of Bioworld Today

“More than 240 million surgeries are performed worldwide each year, yet there is no approved product on the market to prevent the dermal scarring that can frequently occur,” writes Jennifer Boggs, managing editor of BioWorld Today in her cover story on ScarX Therapeutics.

The article, “ScarX Finds New Uses for Old Drug in Dermal Scarring,” appeared in the New Co section and focuses on the MaRS Innovation-Hospital for Sick Children start-up company.

Here’s an excerpt:

“ScarX Therapeutics, a 2012 Toronto-based start-up, is looking to introduce a topical anti-scarring product onto the market — a product that can be administered by the patient — to prevent scarring following surgical procedures.

BioDiaspora Founder Kamran Khan interviewed in Maclean’s Magazine

February 12, 2013
Susanne Staer
BlueDot

India’s Kumbh Mela, an annual mass Hindu pilgrimage of faith, is unlikely to create a disease outbreak that spreads beyond the country’s borders, Dr. Kamran Khan, founder of BioDiaspora, tells Maclean’s Magazine‘s Hannah Hoag in “As millions gather for Kumbh Mela, doctors are watching” (February 11, 2013).

Here’s an excerpt (emphasis ours):

Unlike the hajj or the Olympics, the Kumbh Mela is primarily a domestic event. While flights into Saudi Arabia spike to five times normal during the hajj, “with the Kumbh Mela, it’s marginal,” says Khan, “probably five to 10 per cent at some airports.”

To help stem disease outbreaks that do cross borders, such as the 2003 SARS outbreak in Toronto, Khan developed Bio.Diaspora, an online tool that shows how international travellers can spread infectious diseases. Khan is also working with another group of scientists—along with the U.S. Centers for Disease Control and Prevention (CDC)—to develop a tool called BioMosaic that maps census data, migration patterns and health status to identify countries where international travel may give rise to emerging disease.

UTEST program: Giving U of T students a new way to become their own bosses

February 6, 2013
Susanne Staer
Media Coverage

The Varsity's coverage of the UTEST program — The Varsity’s coverage of the UTEST program. Photographed at the bottom left is **Will Walmsley**, founder of Whirlscape.

“There is a path somewhere between extended study and becoming an office worker,” wrote The Varsity‘s Angela Brock, in “Be Your Own Boss: Student entrepreneurs combine creativity and business to forge new career paths” (February 3, 2012). “As it turns out, there are plenty of opportunities for those looking to flex their entrepreneurial muscles without straying too far from the bosom of U of T.”

Brock’s article describes UTEST, the joint U of T-MaRS Innovation program that helps students, faculty and recent alumni commercialize software ideas.

It also profiles Will Walmsley, founder of Whirlscape, and Tyler Lu, co-founder of Granata Decision Systems, about their UTEST experience leading companies created through the program’s first cohort.

DLVR: Using personalized medicine and nature’s cellular toolkit to target cancer tumours

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. This post coincided with World Cancer Day.

What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy?

Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver drugs designed to deactivate cancer-promoting genes within the tumour, while minimizing the addition of toxins to the patient’s body.

Personalized medicine research in Toronto also benefited from a recent $50 million donation to support Princess Margaret Hospital (part of the University Health Network). Read and watch the news announcement on BioTechnology Focus.

This is personalized medicine’s promise for cancer treatment: targeted therapies that stand a better chance of success, with reduced side effects, based on the unique profile of a patient’s tumour, either administered on their own or in combination with traditional chemotherapy.

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

TORONTO, ON (Jan. 24, 2013) – ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from Ontario Centres of Excellence.

This story was covered in Yonge Street Media on January 30, 2013.

ScarX, a topical medication, emerged from Dr. Benjamin Alman‘s research. Alman, head of orthopedic surgery at the Hospital for Sick Children, is developing his invention in conjunction with MaRS Innovation.

Benjamin Alman, founder of ScarX Therapeutics. — **Dr. Benjamin Alman**, founder of ScarX Therapeutics. Photo courtesy of The Hospital for Sick Children.

Each year, doctors worldwide perform 240 million surgeries. Currently, no clinically-proven prescription therapeutic exists to reduce post-surgical scarring. Given this critical need for its technology, ScarX Therapeutics believes sales of the ScarX product could potentially reach into the billions of dollars.

“ScarX is a true game-changer when it comes to reducing the scarring associated with many surgeries,” said Dr. Tom Corr, president and CEO of Ontario Centres of Excellence. “Through our Market Readiness program, OCE is pleased to be supporting both the commercialization of this revolutionary research-based product and Ontario’s economy.”

Globe and Mail and Global News Toronto cover early-stage Bio Printer technology

U of T Ph.D. student Lian Leng demonstrates how the Bio Printer prototype creates new skin cells. — U of T Ph.D. student **Lian Leng** demonstrates how the Bio Printer prototype creates new skin cells. Screen shot courtesy of Global News Toronto.

An early-stage technology that may revolutionize the way burn victims are treated is generating considerable buzz in Toronto media this week.

Globe and Mail reporter Robert Everett-Green wrote about the joint University of Toronto and Sunnybrook Health Sciences Centre project January 20 in “A 3-D machine that prints skin? How burn care could be revolutionized.”

Health reporter Beatrice Politi also covered the Bio Printer project for Global News Toronto January 21. Her video segment includes an interview with PhD student Lian Leng and a look at the existing Bio Printer prototype.

Xconomy names Xagenic to 2012’s Biotech Startup Class

January 18, 2013
Susanne Staer
Awards

MI spin-off company one of 30 listed in North America and the United Kingdom

Xconomy, a U.S.-based business news website, named Xagenic to its 2012 Biotech Startup Class.

Luke Timmerman‘s article, published December 3, 2012, sited Xagenic as one of only 30 “exciting biotech startups” to raise significant venture capital (at least $5 million) in the life sciences sector.

Xagenic, founded by Drs. Shana Kelley and Ted Sargent at the University of Toronto, was also the only Canadian company named to the list.

Video: Dr. Raphael Hofstein’s interview with IBTimesTV

December 14, 2012
Susanne Staer
Media Coverage

Technology reporter Alastair Charlton speaks to Dr. Raphael Hofstein, president and CEO of MaRS Innovation, about how Tech City in the U.K. can learn from Canada’s hub for science, technology and social entrepreneurs.

Minuum to end battle between mobile screen space and virtual keyboards

Crowdmark’s grading software featured in EdSurge

ScarX Therapeutics featured on cover of Bioworld Today

BioDiaspora Founder Kamran Khan interviewed in Maclean’s Magazine

UTEST program: Giving U of T students a new way to become their own bosses

DLVR: Using personalized medicine and nature’s cellular toolkit to target cancer tumours

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

Globe and Mail and Global News Toronto cover early-stage Bio Printer technology

Xconomy names Xagenic to 2012’s Biotech Startup Class

MI spin-off company one of 30 listed in North America and the United Kingdom

Video: Dr. Raphael Hofstein’s interview with IBTimesTV

Quick Links

Contact Us